Insmed (INSM) Capital Expenditures Growth (3y) (2014 - 2026)
Powered by 
Analysis
Insmed (INSM) Capital Expenditures Growth (3y) (2014 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 23.70% |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 0.24% |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 23.48% |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 63.07% |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | -45.93% |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 29.63% |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | -16.79% |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 27.08% |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn | 4.64% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 27.08% |
| Mar 31, 2026 | -12.70% |
| Dec 31, 2025 | 10.73% |
| Sep 30, 2025 | 43.65% |
| Jun 30, 2025 | 36.92% |
| Mar 31, 2025 | -53.50% |
| Dec 31, 2024 | 25.32% |
| Sep 30, 2024 | 175.62% |
| Jun 30, 2024 | -108.36% |
| Mar 31, 2024 | -38.10% |
| Dec 31, 2023 | 49.21% |
| Sep 30, 2023 | 126.01% |
| Jun 30, 2023 | 17.48% |
| Mar 31, 2023 | 24.99% |
| Dec 31, 2022 | -2.14% |
| Sep 30, 2022 | -29.50% |
| Jun 30, 2022 | 6.77% |
| Mar 31, 2022 | -3.71% |
| Dec 31, 2021 | 4.37% |
| Sep 30, 2021 | -42.28% |